글로벌 뇌졸중 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

뇌졸중 시장 분석

글로벌 뇌졸중 시장은 뇌졸중 예방에 대한 인식 증가와 치료 옵션의 발전으로 인해 상당한 성장을 목격하고 있습니다. 전 세계적으로 장애와 사망의 주요 원인인 뇌졸중으로 인해 의료 시스템은 조기 진단, 효과적인 치료 및 재활에 집중하게 되었습니다. 최근 시장의 발전에는 혈전 제거 장치 및 고급 영상 기술과 같은 혁신적인 치료법의 도입이 포함되며, 이를 통해 더 빠르고 정확한 진단 및 개입이 가능해졌습니다. 예를 들어 FDA가 Penumbra 5 MAX 흡인 시스템을 승인하면서 허혈성 뇌졸중 환자를 위한 기계적 혈전 제거 시술의 효능이 향상되었습니다. 또한 원격 의료의 통합으로 환자 관리가 혁신되어 원격 모니터링 및 상담이 가능해졌으며, 이는 전문 치료에 대한 접근성이 제한될 수 있는 농촌 지역에서 특히 유익합니다. 게다가 뇌졸중 증상과 위험 요인에 대한 대중 교육을 목표로 하는 이니셔티브도 조기 발견 및 치료에 기여하여 시장 성장을 더욱 촉진하고 있습니다.

뇌졸중 시장 규모

글로벌 뇌졸중 시장 규모는 2023년에 325억 7천만 달러로 평가되었으며, 2031년까지 580억 9천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 7.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

뇌졸중 시장 동향

“ 뇌졸중 치료를 위한 원격진료 도입 증가”

글로벌 뇌졸중 시장은 뇌졸중 예방에 대한 인식 증가와 치료 옵션의 발전으로 인해 상당한 성장을 목격하고 있습니다. 뇌졸중 시장의 중요한 추세는 뇌졸중 치료를 위한 원격 의료 도입이 증가하고 있다는 것입니다. 이는 시기적절한 진단과 치료를 향상시킵니다. 원격 의료를 통해 의료 서비스 제공자는 원격으로 상담을 진행하여 뇌졸중 증상을 겪는 환자를 신속하게 평가할 수 있습니다. 이러한 접근 방식은 특히 전문적인 뇌졸중 치료에 대한 접근성이 제한될 수 있는 농촌이나 서비스가 부족한 지역에서 매우 중요한 것으로 입증되었습니다. 예를 들어, 다양한 의료 기관에서 시행하는 TeleStroke 프로그램을 통해 신경과 전문의는 화상 회의를 통해 환자를 평가하여 뇌졸중 발병 후 중요한 "황금 시간" 내에 중환자 치료 결정을 내릴 수 있습니다. 이러한 시기적절한 개입은 혈전 용해 요법을 시행하는 데 필수적이며, 이는 환자 결과를 크게 개선할 수 있습니다. 기술이 계속 발전함에 따라 뇌졸중 관리에 원격 의료를 통합하면 치료 프로세스가 간소화되고 환자 참여와 교육이 향상되어 궁극적으로 뇌졸중 시장에서 회복률이 향상되고 의료비가 절감됩니다.

보고서 범위 및 뇌졸중 시장 세분화       

Stroke Market Definition

A stroke, also known as a cerebrovascular accident (CVA), occurs when the blood supply to a part of the brain is interrupted or reduced, preventing brain tissue from receiving oxygen and nutrients. This disruption can be caused by either a blockage of blood vessels (ischemic stroke) or the rupture of a blood vessel (hemorrhagic stroke). The lack of blood flow can lead to brain cell death within minutes, resulting in varying degrees of disability, depending on the affected brain region and the duration of the interruption.

Stroke Market Dynamics

Drivers

• Increasing Incidence of Stroke

The increasing incidence of stroke is a pressing global health issue, with statistics showing that approximately 15 million people worldwide suffer a stroke each year, according to the World Health Organization (WHO). This rise can be largely attributed to aging populations, as the risk of stroke increases with age, particularly in individuals over 65. In addition, lifestyle changes, including sedentary behavior, poor diet, and smoking, have led to a surge in risk factors such as hypertension, diabetes, and obesity. As a result, the growing number of stroke cases is significantly driving demand for effective treatments, rehabilitation therapies, and advanced diagnostic tools to enhance patient outcomes and reduce the overall burden of this debilitating condition, driving the market growth.

• Rising Prevalence of Hypertension and Coronary Heart Disease Patients

Hypertension, often referred to as high blood pressure, is a medical condition marked by an increased force of blood exerted against the artery walls. Coronary heart disease (CHD), also known as coronary artery disease, develops from the gradual buildup of fatty deposits (atherosclerosis) in the coronary arteries, which deliver essential oxygen and nutrients to the heart muscle. There is a close connection between stroke and the rising prevalence of hypertension and CHD, as they share common risk factors and underlying physiological mechanisms. Specifically, high blood pressure significantly heightens the risk of stroke by damaging blood vessels and increasing the likelihood of blood clot formation. Chronic hypertension can lead to atherosclerosis, resulting in the narrowing of blood vessels and reduced blood flow to the brain, which in turn escalates the risk of both ischemic strokes (caused by blockages) and hemorrhagic strokes (caused by bleeding). In addition, elevated blood pressure can compromise the integrity of blood vessels in the brain, making them more susceptible to rupture or blockage, thereby further increasing the risk of stroke. As the prevalence of hypertension and CHD rises, the demand for effective stroke prevention and treatment options will continue to grow, driving the market for innovative diagnostic tools and therapeutic interventions.

Opportunities

• Increasing Development of Novel Therapies

The development of novel therapies represents a significant market opportunity in the stroke treatment space, as ongoing R&D in pharmaceuticals continues to advance. Key areas of focus include neuroprotective agents that aim to protect brain cells during and after a stroke, stem cell therapies that promote brain tissue regeneration, and innovative clot-busting drugs such as new-generation tissue plasminogen activators (tPA) that work more effectively within a broader treatment window. For instance, the advancement of stem cell-based therapies, such as MultiStem developed by Athersys, has shown promise in promoting neurological recovery by reducing inflammation and protecting damaged neurons, particularly in ischemic stroke patients. These novel approaches address unmet medical needs and create new avenues for pharmaceutical companies to capture market share, especially as these therapies move from clinical trials toward commercial availability. This growing pipeline of innovative treatments is anticipated to significantly expand the stroke treatment market as demand for more effective and less invasive options increases globally.

• Increasing Advancements in Technology

Advancements in technology present substantial opportunities for companies in the stroke market to improve treatment and management through the development of innovative medical devices and tools. For instance, thrombectomy devices, which are designed to remove blood clots from the brain, have revolutionized acute stroke care, enabling faster and more effective interventions that can dramatically reduce the risk of long-term disability. In addition, AI-powered diagnostic tools are emerging as crucial assets in stroke detection, providing rapid and accurate analysis of imaging data, which can facilitate timely decision-making. Companies such as Medtronic and Penumbra are leading the way with their advanced thrombectomy devices that have significantly improved patient outcomes. The integration of Such technologies enhances clinical efficacy and positions companies to capture a larger share of the growing stroke treatment market, making this technological advancement a key market opportunity for innovation and competitive advantage.

Restraints/Challenges

• Managing Stroke in Patients with Multiple Chronic Conditions

Managing stroke in patients with multiple chronic conditions poses significant challenges, as these concurrent health issues can complicate both treatment and recovery. One major complication arises from polypharmacy and medication interactions, where patients with multiple chronic conditions often require numerous medications. This situation increases the risk of drug interactions and adverse effects, making medication management particularly complex in stroke care. For instance, the use of anticoagulants or antiplatelet medications requires careful consideration to balance the risks of bleeding and clotting. As the prevalence of stroke patients with multiple chronic conditions rises, the complexities associated with polypharmacy present a notable market challenge, highlighting the need for innovative solutions to ensure safe and effective medication management.

• Significant Expenses Related to Stroke Treatment

The substantial costs associated with stroke treatment represent a significant concern within the healthcare landscape, affecting both patients and healthcare systems. The initial phase of stroke care entails emergency medical services, including ambulance transport, emergency room assessments, and diagnostic imaging such as CT scans and MRIs. The urgent nature and complexity of these services contribute to escalating expenses. As a result, the high financial burden of stroke treatment poses a considerable market challenge, hampering the overall development of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Stroke Market Scope

The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Ischemic Stroke
• Transient Ischemic Attack (TIA)
• Hemorrhage Stroke

Treatment

• Medication
• Surgery
• Other Therapy

Diagnosis

• Imaging Test
• Blood Test
• Echocardiogram
• Lumbar Puncture
• Other

Gender

• Female
• Male

End User

• Hospitals & Clinics
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare
• Laboratories
• Others

Distribution Channel

• Direct
• Retail
• Online

Stroke Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the stroke market, driven by its strong presence of major industry players and its status as the largest consumer market with a high GDP. The region benefits from substantial investments in healthcare innovation and advanced medical technologies. The U.S., in particular, is set to dominate the North American market due to its continuous advancements in stroke-related products and cutting-edge treatment options, further boosting the market's growth potential.

Germany is expected to lead the European market, primarily due to the strong presence of key industry players and its well-established healthcare infrastructure. This strategic position allows Germany to drive innovation and growth in the region, further solidifying its market dominance.

China is anticipated to dominate the Asia-Pacific region, driven by the rising incidence of stroke and a growing demand from emerging markets. In addition, China's ongoing healthcare expansion and investments in medical advancements further strengthen its position in the regional market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Stroke Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Stroke Market Leaders Operating in the Market Are:

• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Boehringer Ingelheim International GmbH (Germany)
• Sanofi (France)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Teva Pharmaceuticals USA, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• AstraZeneca (U.K.)
• Viatris Inc. (U.S.)
• Lupin (India)
• Abbott (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Penumbra, Inc. (U.S.)
• Oxford Laboratories Pvt. Ltd. (India)
• Sandoz Group AG (Switzerland)
• GLENMARK PHARMACEUTICALS LTD. (India)
• Fresenius SE & Co. KGaA (Germany)
• Amneal Pharmaceuticals LLC (U.S.)

Latest Developments in Stroke Market

• In October 2024, Siemens Healthineers announced its collaboration with over 20 industry and public partners, including seven prominent stroke hospitals, to enhance stroke management for patients throughout Europe. The five-year 'UMBRELLA' project, with a total budget of USD 29.30 million, is being funded in part by the Innovative Health Initiative (IHI), a public-private partnership aimed at health research and innovation between the European Union and the life sciences sector in Europe, as well as contributions from industry partners involved in the consortium
• 2024년 9월, 미시간에 본사를 둔 의료 기기 선두주자 Stryker는 신경 기술 및 뇌졸중 치료 포트폴리오를 강화하기 위해 Nico Corporation 인수를 완료했습니다. 이 인수에는 BrainPath 및 Myriad로 알려진 뇌내출혈(ICH) 치료를 위한 수술을 관리하도록 특별히 설계된 시스템이 포함됩니다. Stryker는 Nico의 혁신적인 기술을 통합하여 신경 기술 분야에서 자사의 제품을 강화하고 뇌졸중 관련 질환을 앓고 있는 환자의 치료 옵션을 개선하고자 합니다.
• 2024년 8월, Christian Medical College(CMC) Vellore와 IIT Madras는 손 운동 요법을 통해 뇌졸중 생존자의 회복을 돕는 것을 목표로 하는 PLUTO(Plug-and-Train Robot for Hand Neurorehabilitation)라는 휴대용 로봇 장치를 공개했습니다. 이 혁신적인 장치는 저렴하고 사용자 친화적으로 제작되어 병원, 소규모 진료소, 커뮤니티 센터, 심지어 집에서도 다양한 환경에서 사용할 수 있는 접근성을 보장합니다.
• 2024년 2월, 뇌졸중 치료를 위한 혁신적인 급성 혈전 용해 요법 개발에 집중하는 임상 단계의 바이오제약 회사인 Basking Biosciences는 5,500만 달러 규모의 자금 조달 라운드를 완료했다고 발표했습니다. 이 라운드는 새로운 투자자인 ARCH Venture Partners가 주도했으며, 기존 투자자인 Longview Ventures, Rev1 Ventures, The Ohio State University와 함께 Insight Partners, Platanus, Solas BioVentures, RTW Investments를 포함한 다른 새로운 투자자들이 참여했습니다.
• 2022년 5월, 오사카 수도권 대학의 연구자들은 만성 단계에서 뇌졸중 회복을 위한 유망한 치료법으로 로봇 요법을 탐구하기 시작했습니다. 로봇 요법이 널리 채택된다면 치료 직원의 직접적인 감독이 거의 필요 없는 비용 효율적인 솔루션을 제공하여 뇌졸중 환자 치료를 향상시킬 수 있습니다.
• 2022년 4월, 미국 국립보건원(NIH)은 인공적으로 성장하고 단순화된 미니 장기를 개발하는 프로젝트에 180만 달러의 자금을 지원했습니다. 이 뇌와 유사한 미니 장기는 뇌졸중으로 손상된 뇌 세포를 표적으로 삼는 새로운 약물을 만드는 데 사용할 수 있는 입자를 생산하도록 설계되었습니다.

SKU-60379